News

Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Digital & Data,Medical devices
OSF HealthCare expands RapidAI clinical AI platform to all 18 hospitals
read more
Central Nervous System,Clinical & Regulatory,Research & Development,Therapeutic Areas
Zilucoplan accepted for eligible myasthenia gravis patients in NHS Scotland
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics
FDA issues Complete Response Letter for ITM-11 over manufacturing issues
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Grifols completes Phase 3 SPARTA study of Prolastin-C in alpha-1 emphysema
read more
Digital & Data,Drug Discovery & Development,Research & Development
Novo Nordisk and AWS launch London AI hub to accelerate drug discovery
read more
Clinical & Regulatory
Acarizax accepted for house dust mite allergy treatment in NHS Scotland
read more
Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Almirall and CrystalO partner on small-molecule drug discovery in dermatology
read more
Advanced Therapies,Drug Discovery & Development,Genomics and sequencing
Broken String Biosciences launches BaseMap ABE for genome-wide off-target analysis
read more
Central Nervous System,Drug Discovery & Development,Research & Development
AstronauTx exercises Saniona option for neurological disease candidate
read more
Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain,Research & Development
European consortium demonstrates continuous API manufacturing platform
read more
Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
BioVie reports Phase 2 Parkinson’s trial results for bezisterim
read more
Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Research & Development
LifeMine raises $263 million to advance transplant rejection therapy into Phase 2
read more
Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
Kupando doses first patient in Phase 1 trial of KUP101 for advanced skin cancer
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics
Adneuris licenses cebranopadol to Maruishi in $35M Japan and South Korea deal
read more
Clinical & Regulatory,Medical devices,Therapeutic Areas
BlueWind wins FDA clearance for longer-lasting Revi implant for urinary incontinence
read more
Digital & Data,Drug Discovery & Development,Research & Development
AI virtual screening tool boosts hit rate 100-fold on challenging drug targets
read more

OSF HealthCare expands RapidAI clinical AI platform to all 18 hospitals

Zilucoplan accepted for eligible myasthenia gravis patients in NHS Scotland

FDA issues Complete Response Letter for ITM-11 over manufacturing issues

Grifols completes Phase 3 SPARTA study of Prolastin-C in alpha-1 emphysema

Novo Nordisk and AWS launch London AI hub to accelerate drug discovery

Acarizax accepted for house dust mite allergy treatment in NHS Scotland

Almirall and CrystalO partner on small-molecule drug discovery in dermatology

Broken String Biosciences launches BaseMap ABE for genome-wide off-target analysis

AstronauTx exercises Saniona option for neurological disease candidate

European consortium demonstrates continuous API manufacturing platform

BioVie reports Phase 2 Parkinson’s trial results for bezisterim

LifeMine raises $263 million to advance transplant rejection therapy into Phase 2

Kupando doses first patient in Phase 1 trial of KUP101 for advanced skin cancer

Adneuris licenses cebranopadol to Maruishi in $35M Japan and South Korea deal

BlueWind wins FDA clearance for longer-lasting Revi implant for urinary incontinence

AI virtual screening tool boosts hit rate 100-fold on challenging drug targets

main menu

recent posts

Leicester clinic offers Galleri blood test following NHS cancer trial

Lonza launches rapid custom media service for early bioprocess development

TraceLink MINT transaction volume surges 183% in 2026

get connected